Canadian multicenter azidothymidine trial AZT pharmacokinetics study objective pharmacokinetics azidothymidine AZT large population early asymptomatic human immunodeficiency virus HIV individuals study design multicenter prospective descriptive single-dose pharmacokinetic study fasting male HIV-infected homosexuals years age CDC classifications II III single oral dose AZT subsequent pharmacokinetic measurements period AZT major metabolite glucuronylazidothymidine GAZT Results patients smokers nonsmokers hepatic dysfunction normal hepatic function following parameters AZT area curve AUC SD microM.h maximum concentration Cmax SD microM time concentration Tmax SD half-life SD Corresponding values GAZT AUC SD microM.h Cmax SD microM Tmax SD SD No significant differences comparisons study site CDC classification disease smokers nonsmokers patients hepatic dysfunction AUC Cmax AZT latter group AZT pharmacokinetics similar patients early asymptomatic HIV disease previous reports patients later disease 